![](https://monteverdelaw.com/wp-content/uploads/case-logo/immunogen-inc.png)
ImmunoGen, Inc. (Nasdaq: IMGN), relating to its proposed sale to AbbVie Inc. Under the terms of the agreement, IMGN shareholders will receive $31.26 in cash per share they own.
ImmunoGen, Inc. (Nasdaq: IMGN), relating to its proposed sale to AbbVie Inc. Under the terms of the agreement, IMGN shareholders will receive $31.26 in cash per share they own.